Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion type Assertion NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_head.
- NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion description "[It is further hypothesized that MC2R blockade should allow using lower glucocorticoid doses to treat congenital adrenal hyperplasia (CAH) due to enzyme deficiency of either 21-hydroxylase (CYP21B) or 11-hydroxylase (CYP11B1), thus reaching a better final adult height than with current therapeutic strategies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_provenance.
- NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion evidence source_evidence_literature NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_provenance.
- NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion SIO_000772 19931309 NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_provenance.
- NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion wasDerivedFrom befree-2016 NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_provenance.
- NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_assertion wasGeneratedBy ECO_0000203 NP777147.RACKaMXS3wrgJ57qdXwRvwCGpsfe2KaQczNw_nI8KCbhg130_provenance.